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Abstract: Scopolamine (SCP: 0.5, 2 and 8 mg/kg s.c.), a muscarinic anti-cholinergic drug, dose-dependently increased 
the ambulatory activity of mice for 90 min with the peak effect around 10-20 min after the administration. A significant 
tolerance to the ambulation-increasing effect of SCP was produced when the mice were repeatedly administered SCP at 
intervals of 3 days, and they were put into the activity cages of 20 cm in diameter for 90 min after each administration. 
The mice allowed free ambulation in the activity cages during post-SCP period of 10-60 min, particularly 10-30 min, 
showed a tolerance to SCP. However, no significant tolerance or sensitization was produced when the ambulation of 
mice was allowed during the post-SCP period of 0-10min or 60-90 min. The repeated saline-treatment with free or 
restricted movement produced no significant change in the sensitivity to SCP. The present results suggest that the repeated 
experience of both the muscarinic anti-cholinergic effect of SCP and the free ambulation during the early post-SCP period 
of 10-30 min is the essential factor for the induction of tolerance to the ambulation-increasing effect of SCP in mice. 
Such development of the behavioral tolerance to SCP may be due to the psychopharmacological characteristics of SCP 
that the harmful symptoms such as dry mouth and eyes produced by blockade of parasympathomimetic nervous systems 
overwhelm the reward effect (dependence liability) of this drug.
(Reprint request should be sent to Hisashi Kuribara)
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Introduction
Scopolamine (SCP) has an antagonistic action on mus-
carinic acetylcholine receptors, and blocks the parasympa-
thomimetic nervous system. It has been considered that 
central dopaminergic system (Fink and Morgenstern, 
1980) and cholinergic systems (Mathura et al., 1997; Shan-
non and Peters, 2001; Chintoh et al., 2003) are involved in 
the SCP-induced hyperactivity. Furthermore, SCP is self-
administered by animals (Glick and Goido, 1982; Rasmus-
sen and Fink-Jensen, 2000), and a short-term recreational 
use of SCP (Brunton et al., 2008) and Angel’ s trumpet 
(Greene et al., 1996) which is a plant containing muscarin-
ic anti-choinergic drugs such as SCP and atropine has been 
reported, indicating dependence liability of SCP.
Mesolimbic dopaminergic systems (Van der Heuval and 
Pasterkamp, 2008) play important roles in the behavioral 
and psychological activities, including motivation (Matsu-
moto and Hikosaka, 2009), learning and memory (Arias-
Carrion and Poppel, 2007), drug dependence and abuse 
(Schultz, 2002; Piercem and Kumaresan 2006; Berridge, 
2007; Ikemoto, 2007), pain and analgesia (Wood, 2008), 
and psychic symptoms (Diaz, 1996; Laviolette, 2007).
It has been demonstrated that the repeated administra-
tions of psychomotor stimulants such as methamphetamine 
and cocaine as well as narcotic analgesics such as mor-
phine induced sensitization to their ambulation-increasing 
effect in mice, and that the induction of sensitization could 
be inhibited when mice were placed in a small jar (6 cm in 
diameter) after each drug administration (Kuribara and 
Tadokoro, 1989; Kuribara. 1995a,b, 1996a,b). In such a 
narrow space, expression of the ambulation (horizontal 
movement), but not turning and vertical movements, can 
be perfectly inhibited without blocking the pharmacologi-
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cal effect. Furthermore, the present author found that an 
early post-drug period before attaining to the peak effect 
was important to induce a significant sensitization to the 
ambulation-increasing effect of psychomotor stimulants 
and narcotic analgesics (Kuribara, 1996b, 2009, 2010). 
The restraint did not block the pharmacological effect of 
drugs. Such results bring a consideration that a repeated 
experience of both the pharmacological effect of drug and 
the resultant ambulation during the early post-drug period 
is the minimum requirement for induction of the sensitiza-
tion to ambulation-increasing effect of psychomotor stimu-
lants and narcotic analgesics, i.e., conditioning (learning 
and memory) of the behavioral output. It is also suggested 
that the behavioral sensitization is closely related to the 
dependence liability of drugs (Kuribara and Hirabayashi, 
1985; Pert et al., 1990).
Different from the characteristics of the ambulation-
increasing effects of psychomotor stimulants and narcotic 
analgesics, the repeated administration of SCP to the mice 
at intervals of 1 day or longer resulted in a significant 
decrease in the ambulation-increasing effect (Kuribara and 
Tadokoro, 1983, 1987). These results bring a question 
whether the decrease in the ambulation-increasing effect of 
SCP is produced by the tolerance to the pharmacological 
effect of SCP, or by the behavioral tolerance, namely con-
ditioning, dependent on the environmental factors.
The aims of this study were to assess the modification 
by the environment of the SCP-induced ambulatory stimu-
lation following the repeated administration. The free 
ambulation of mice was limited after the post-SCP period.
Materials and Methods
Animals 
Male mice of the ddY strain (SLA Japan, Hamamatsu) 
were used when they attained at 6 weeks of age and a 
weight of 25-28 g. Groups of 10 mice each had been 
housed in polycarbonate cages (20W × 25L × 15H cm) 
with free eating a solid diet (MF: Oriental Yeast, Tokyo) 
and tap water except during the behavioral tests. The con-
ditions of the breeding room were controlled (temperature; 
23 ± 1 °C, relative humidity; 55 ± 3 %, and a 12:12-hr 
light-dark cycle; lights on between 06:00-18:00 hr). The 
temperature and relative humidity of experimental room 
were almost the same as the breeding room.
All the experimental treatments mentioned below were 
carried out according to “The Guiding Principles for the 
Care and Use of Laboratory Animals” of The Japanese 
Pharmacological Society.
Apparatus 
The ambulatory activity of 10 mice was individually 
and simultaneously measured with “ambulometer” which 
had 10 tilting-type Plexiglas activity cages of 20 cm in 
diameter and 15 cm in height (SMA-10: O’hara & Co., 
Tokyo) (Fig.1). The apparatus selectively detected hori-
zontal movements (ambulation), but not turning, or verti-
cal movements such as rearing, head movement or 
sniffing, of the mouse.
To selectively restrict the ambulation of mice, glass jars 
(6 cm in diameter and 15 cm in height) were used. In the 
jar, the mouse could almost freely express vertical move-
ments and turning.
Drug
The drug used was scopolamine HBr (SCP: Sigma 
Chemical, St. Louis, MO). SCP was dissolved in physio-
logical saline, and subcutaneously (s.c.) administered at a 
constant volume of 0.1 ml/10 g body weight of the mouse 
independent of the doses of SCP. The doses of SCP were 
expressed in the salt form.
Fig. 1.  The ambulometer for selective measurement of 
horizontal movement of the mouse.
1: Microswitches for detection of the mouse’s movement. 
2: Stoppers of the activity cage. 
3. Falcrum of the activity cage.
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Experimental schedules 
All the experimental treatments; the administration of 
SCP, putting the mouse in the glass jar and measurement 
of ambulation of the mice, were carried out between 
09:00-16:00 hr.
In the case of measurement of the activity of mice, they 
were individually put in the activity cages for 10 min, and 
then the administration of SCP or saline was conducted. 
The activity of each mouse was measured at intervals of 10 
min for 90 min.
1) Determination of the optimum dose of SCP
Four groups of mice (10 mice each) were administered 
SCP (0: saline, 0.5, 2 and 8 mg/kg s.c.), and their activity 
were measured for 90 min.
In addition, the other one group of 10 mice was treated 
with SCP (2 mg/kg) + free movement for 5 times at inter-
vals of 3 days.
2) Repeated SCP administration with limited ambulation
Ten groups of mice (10 mice each) were given SCP (2 
mg/kg), and they were allowed to freely move in the activity 
cage during the post-SCP period of either 0-10, 0-20, 0-30, 
0-60, 10-30, 10-60, 10-90, 30-60, 30-90 or 60-90 min. 
During the other periods by 90 min after the SCP adminis-
tration, these mice were individually put into the small jars 
to restrict their ambulation. As the control administration for 
SCP, other 10 groups of mice were given saline, and allowed 
ambulation in the activity cage in the same schedules as in 
the SCP study. In addition, two sets of 2 groups of mice (10 
mice each) were given either SCP or saline, and then put in 
the activity cages (free ambulation) or in the jars (perfect 
restraint) for 90 min. Such pretreatments were carried out 5 
times at 3-day intervals.
Three days after the final (5th) pretreatment, SCP was 
challenge-administered to all groups of mice, and their 
ambulatory activities were measured for 90 min.
Statistical analysis
Since the durations of measurement of the ambulatory 
activity were different among groups of mice in the pre-
treatment phase, the mean activity counts in each group 
were analyzed by one-way analysis of variance (ANOVA). 
In the challenge administration phase, the data were ana-
lyzed by two-way ANOVA.  Post-hoc analyses were car-
ried out by Bonferroni test. Values of p less than 0.05 were 
considered significant. 
Results
Time-courses of change in the SCP-induced activity
As shown in Fig. 2, SCP-induced ambulatory stimula-
tion attained to the peak level during the period of 10-20 
min, and almost ceased by 90 min after the administration.
Repeated administration of SCP
The repeated administration of SCP (2 mg/kg) induced 
progressive decrease in the ambulation-increasing effect 
(Fig. 3). However, no marked change in the latency to the 
peak effect or duration of the effect was produced.
Table 1 shows the activity counts following five repeated 
administrations of SCP with limited ambulation during the 
various post-SCP periods.
The repeated administration of SCP resulted in a signifi-
cant tolerance to the ambulation-increasing effect in the 
Fig. 2.   Time-courses of change in the scopolamine (0: 
saline, 0.5, 2 and 8 mg/kg s.c.)-induced ambulatory 
stimulation in mice. N=10 in each group.
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groups of mice with free ambulation during post-SCP peri-
ods of 10-60min, but not in the groups of mice with free 
ambulation during post-SCP periods of 0-10 min and 
60-90 min. The development of tolerance was much 
marked in the groups with the free ambulation during the 
early post-SCP periods of 10-30 min.
The activity of the saline-administered mice with free or 
limited ambulation were very low (15-68 counts) in the 1st 
administration, and no significant changes in the activity 
counts were demonstrated throughout the five repeated 
administrations (data not shown).
Challenge administration of SCP
Table 2 shows mean 90 min activity counts following 
the challenge administration of SCP to the groups of mice 
that had been pretreated with SCP or saline with free or 
limited ambulation.
The groups of mice pretreated with repeated administra-
tion of saline with free or limited ambulation did not show 
significant change in the sensitivity to challenge adminis-
tered SCP.
The activity counts in the groups of mice allowed free 
ambulation during the post-SCP periods of 0-20, 0-30, 
0-60, 10-30, 10-60 and 10-90 min were as high as that in 
the group of mice with no restraint (free ambulation for 90 
min). The groups of mice allowed free ambulation during 
Fig. 3.   Time-courses of change in the mean ambulatory 
activity count following five administrations of 
scopolamine (2 mg/kg s.c.) at 3-day intervals to the 
mice. N=10.
Table 1.  Activity counts after the repeated administration of scopolamine (2 mg/kg s.c.) at 3-day intervals.
Period of free movement 1st 2nd 3rd 4th 5th
0-90min 523±61 262±28* 172±15* 124±15* 106±13*
0-10 72±  7 68±  7 65±  5 55±  6 56±  7
0-20 169±15 112±11* 78±  8* 59±  7* 65±  9*
0-30 260±21 151±17 103±11* 77±  9* 73±  6*
0-60 468±45 218±22* 147±18* 101±11* 74±  7*
10-30 170±13 103±  8* 69±  6* 50±  4* 49±  6*
10-60 393±50 194±26* 131±16* 83±10* 70±  8*
10-90 490±69 221±33* 49±17* 107±15* 109±13*
30-60 202±21 144±18 103±  9* 69±  5* 58±  6*
30-90 299±33 254±22 203±20* 199±15* 156±13*
60-90 85±11 79±  8 73±  6 79±12 72±  9
N=10 in each group. *: p<0.05 vs. the 1st administration within each group.
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the post-SCP periods of 30-60 and 30-90 min demonstrated 
partial tolerance. However, the activity count of the group 
of mice allowed free ambulation during the post-SCP 
periods of 0-10 min showed a slight, but not significant, 
decrease in the sensitivity to the challenge-administered 
SCP. The activity counts of the groups of mice allowed 
ambulation during the post-SCP periods of 60-90 min and 
perfectly restricted for 90 min were almost the same as that 
of the group of mice pretreated with saline with free 
ambulation.
Discussion
It has been considered that central dopaminergic system 
(Fink and Morgenstern, 1980) and cholinergic systems 
(Mathura et al., 1997; Shannon and Peters, 2001; Chintoh et 
al., 2003) are involved in the SCP-induced hyperactivity. In 
some cases, a restraint and even handling of mice including 
injection of drug or saline act as stressors, and result in an 
increased sensitivity to central acting drugs through a stimu-
lation of central dopaminergic and/or opiate systems (Kalivas 
and Stewaet, 1991; Deroche et al., 1992; Shaham et al., 
1995). However, the mice pretreated with saline with free 
and limited ambulation, and even with perfect restraint for 
90 min did not show any significant change in the sensitivity 
to challenge-administered SCP, suggesting that the restraint 
or handling carried out in this study did not alter neurotrans-
missions of dopaminergic, opiate or cholinergic systems.
Generally, the repeated administrations of psychomotor 
stimulants and narcotic analgesics to the mice induce sig-
nificant sensitization to their ambulation-increasing effects, 
and that the early-post drug period before the peak effect is 
the essential factor for induction of sensitization to the 
ambulation-increasing effect (Kuribara, 1995a,b, 1996a,b, 
2009, 2010). The mechanisms of behavioral sensitization 
to psychomotor stimulants and narcotic analgesics are con-
sidered to be basically identical, i.e., stimulation of the 
mesolimbic dopaminergic systems (Van der Heuval and 
Pasterkamp, 2008; Matsumoto and Hikosaka, 2009) which 
are strongly related to the reward effects, i.e., dependence 
liability (Piercem and Kumaresan 2006; Berridge, 2007; 
Ikemoto, 2007).
Table 2.   Activity counts after the challenge-administration of scopolamine (2mg/kg s.c.) to the mice pretreated  
with scopolamine (2 mg/kg) or saline + limited ambulation for 5 times at 3-day intervals.
Period of free-movement
in the pretreatment sessions
Scopolamine Saline




0-60 105±  7* 505±40
10-30 102±10* 521±51





Perfect restraint for 90min 580±66$ 562±79
N=10 in each group. 
*: p<0.05 vs. the saline-pretreated group with the same condition of free-movement.  
$: p<0.05 vs. the mice with SCP + no restraint.
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Different from the effects of psychomotor stimulants 
and narcotic analgesics, the repeated administration of 
SCP to the mice at intervals of 3 days with the free ambu-
lation in the activity cage induced progressive decrease in 
the ambulation-increasing effect. The chronic treatment of 
SCP causes an increased sensitivity of cholinergic recep-
tors (Marks et al., 1984). However, such pharmacological 
tolerance may not be involved in the decreased ambula-
tion-increasing effect demonstrated in the present experi-
ment. The groups of mice pretreated with SCP with perfect 
restraint for 90 min did not show tolerance to the ambula-
tion-increasing effect of SCP. The restraint selectively 
blocked the expression of ambulation, but not turning or 
vertical movements, without inhibiting the pharmacologi-
cal effects of SCP. It is therefore highly probable that the 
induction of environment-dependent tolerance to the 
ambulation-increasing effect of SCP is specific.
It is interesting to note that groups of mice treated with 
SCP + free ambulation during the post-SCP periods of 
0-20, 0-30, 0-60, 10-30, 10-60 and 10-90 min showed pro-
gressive decrease in the ambulation-increasing effect, and 
that the activity counts at the challenge-administration of 
SCP were as high as that in the group of mice allowed free 
ambulation for 90 min (no restraint). The groups of mice 
allowed ambulation during the post-SCP periods of 30-60 
and 30-90 min showed partial tolerance. However, the 
activity counts of the groups of mice perfectly restricted 
the ambulation for 90 min, or allowed ambulation during 
the post-SCP periods of 0-10 and 60-90 min were almost 
the same as that of the group of mice pretreated with saline 
+ free ambulation, showing no tolerance to the ambulation-
increasing effect of SCP. These results indicate that the 
metabolic or functional tolerance to SCP is scarcely 
involved in the decreased sensitivity to SCP after the 
repeated administration at 3-day intervals, and that the 
repeated experience of symptoms produced by the musca-
rinic anti-cholinergic effect of SCP and ambulation during 
the post-SCP period of 10-30 min, but not 0-10 or 60-90 
min, is an important factor for induction of a significant 
tolerance to the ambulation-increasing effect of SCP., i.e., 
environment-dependent tolerance or behavioral tolerance.
These results suggest that, although SCP stimulates cen-
tral dopaminergic systems through the antagonistic action 
on the muscarinic cholinergic receptors which may be 
related to the reward effect of SCP (Glick and Goido, 
1982; Rasmussen and Fink-Jensen, 2000), the harmful 
symptoms caused by muscarinic anti-cholinergic effect is 
much stronger than the reward effect. Since the restraint in 
the narrow jar selectively inhibits the ambulation of mice 
without blocking the muscarinic anti-cholinergic effect of 
SCP, it is emphasized that the connection of ambulation 
and the harmful symptoms during post-SCP period of 
10-30 min plays extremely important role in the induction 
of significant decrease in the ambulation-increasing effect 
following the repeated administration of SCP. Such mecha-
nism may be basically similar to the induction of behavior-
al sensitization to psychomotor stimulants (Kuribara, 
1995b, 1996a, 2009) and narcotic analgesics (Kuribara, 
2010), although the directions of the change in the effect 
are completely opposite. 
The present results are also consistent with the evidence 
that severe dependence and abuse are rare for the musca-
rinic anti-cholinergic drugs (Sussman and Ames, 2001), 
although a small number of recreational use of SCP and 
SCP-containing plant, Angel’ s trumpet, for short-term has 
been reported (Greene et al., 1996; Brunton et al., 2008). 
The behavioral effect of SCP demonstrated in this study 
may be related to the psychopharmacological characteris-
tics of SCP that the harmful symptoms such as dry mouth 
and eyes produced by blockade of parasympathomimetic 
nervous systems overwhelm the reward effect (dependence 
liability) of this drug.
Conclusion
A significant decrease in the ambulation-increasing 
effect of SCP (2 mg/kg s.c.), an antagonist of muscarinic 
cholinergic receptors, was induced when it was repeatedly 
administered to mice at intervals of 3 days. When the 
ambulation of mice was allowed during the post-SCP 
period of 10-30 min, the tolerance to SCP was perfectly 
induced. However, the allowance of free ambulation during 
post-SCP period of 30-60 min was followed by a partial 
tolerance. Free ambulation during post-SCP period of 0-10 
or 60-90 min produced no tolerance. These results suggest 
that the tolerance to the ambulation-increasing effect of 
SCP is induced by the connection of the ambulation and the 
harmful symptoms caused by the stimulation of the 
parasympathomimetic nervous systems, and that the 
harmful symptoms overwhelm the reward effect of SCP.
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抄録： Scopolamine（2 mg/kg s.c.）は、投与後10-20分の時間帯を最大効果とし、約90分間にわたってマウスの移所運動を
促進した。同一用量の scopolamineを3日間隔で反復投与し、直径20 cmの測定容器によって移所運動を測定すると、運動
促進効果に対する耐性が引き起こされた。Scopolamineの投与後90分間の間に、一定時間にわたってマウスを測定容器内
で、運動を可能とした。それ以外の時間帯は直径6 cmの円筒内に入れて運動を制限した。すると、投与後10～30分の時
間帯に測定容器内で運動を許されたマウスは、90分間にわたって自由に運動させたマウスと同程度の耐性形成を示した。
一方、30～60分の時間帯に運動を許されたマウスでは部分的な耐性形成にとどまり、0～10分あるいは60～90分の時間帯
の運動では耐性形成あるいは増感のいずれも生じなかった。生理食塩水の投与と運動制限の組み合わせは、scopolamine
に対する感受性に全く影響しなかった。これらの結果は、scopolamineの投与から10～60分間、特に10～30分間の時間帯
における薬物効果と運動の両方を経験することが、マウス移所運動促進効果に対する行動的な耐性形成に必須であること
を示している。また、本実験で示されたscopolamineの行動薬理学的特性は、口渇やドライアイといった本薬物の抗コリン
作用に起因する嫌悪感がドパミン神経系の刺激で引き起こされる依存性を上回ることを示唆している。
（別刷請求先：栗原　久）
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